2184. Clinical and Molecular Epidemiology of Carbapenem-Resistant Gram-Negative Bacilli in a Los Angeles Tertiary Medical Center

Abstract Background Multidrug-resistant gram-negative bacilli are a significant public health threat, associated with 2.2 million deaths worldwide. Of particular importance is the rise of carbapenem-resistant gram-negative bacilli (CRGNB) given the limited options for treatment. The 30-day mortality...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open forum infectious diseases 2023-11, Vol.10 (Supplement_2)
Hauptverfasser: Sanchez, John Michael, Contreras, Deisy, Morgan, Margie Ann
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_2
container_start_page
container_title Open forum infectious diseases
container_volume 10
creator Sanchez, John Michael
Contreras, Deisy
Morgan, Margie Ann
description Abstract Background Multidrug-resistant gram-negative bacilli are a significant public health threat, associated with 2.2 million deaths worldwide. Of particular importance is the rise of carbapenem-resistant gram-negative bacilli (CRGNB) given the limited options for treatment. The 30-day mortality associated with carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, and carbapenem-resistant Acinetobacter baumannii ranges from 16 to 24%. In recognition of the substantial danger of these organisms, the World Health Organization has designated three CRGNB as Critical Priority pathogens. Methods Based on culture data and antimicrobial susceptibility testing, patients with CRGNB at Cedars-Sinai Medical Center from December 2022 to April 2023 were identified. Clinical data including patient demographics, prior carbapenem use, isolation of additional antibiotic-resistant organisms, subsequent antibiotic therapy, and mortality were compared among CRGNB. Results Of over 65 isolates, the largest proportion of isolates were cultured from pulmonary sources (44%), followed by urine (34%), skin (12%), blood (6%), and abdominal sources (4%). The most prevalent CRGNB isolated were Pseudomonas aeruginosa (65%), Escherichia coli (13%), and Klebsiella pneumoniae (7%). A majority of patients with CRGNB had prior documented carbapenem use (74%) and 71% of CRGNB were associated with at least one other antibiotic resistant organism. Cefiderocol was used to treat 12% of cases. However, 24% of CRGNB were not treated with antibiotics, often with the rationale that the isolate was likely a colonizing strain. The mortality rate among patients with CRGNB during our observation period was 18%. Conclusion CRGNB are emerging pathogens associated with prior carbapenem use and result in significant mortality. Subsets of organisms from our dataset will be further studied for relatedness using Fourier-Transform infrared spectroscopy and whole genome sequencing. Disclosures All Authors: No reported disclosures
doi_str_mv 10.1093/ofid/ofad500.1806
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ofid_ofad500_1806</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ofid/ofad500.1806</oup_id><sourcerecordid>10.1093/ofid/ofad500.1806</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1226-bc99d55b4e5ab652f8c15d23d1b2e8f5da027216bd00025dbc38a810caf2fb233</originalsourceid><addsrcrecordid>eNqNkMFOwzAMhiMEEtPYA3DLA9CRpEvXHkc1BtIGEhrnykmcKShtpqQg7caj07EdOHKxLcu_f_sj5JazKWdVfh-sM0MAI9nQKVlxQUYiF2VWVnJ--ae-JpOUPhhjnDPJ5tWIfAtezqa09q5zGjyFztBN8Kg_PUS63DuDrQs-7A40WFpDVLDHDtvsDZNLPXQ9XUVosxfcQe--kD6Adt476joKdB0SXXQ79JjoFmPvIB7oBs2vVY1dj_GGXFnwCSfnPCbvj8tt_ZStX1fP9WKdaS5EkSldVUZKNUMJqpDClppLI3LDlcDSSgNMzAUvlBm-E9IonZdQcqbBCqtEno8JP-3VMaQU0Tb76Nrhnoaz5kixOVJszhSbI8VBc3fShM_9P8Z_AGRRdok</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>2184. Clinical and Molecular Epidemiology of Carbapenem-Resistant Gram-Negative Bacilli in a Los Angeles Tertiary Medical Center</title><source>DOAJ Directory of Open Access Journals</source><source>Oxford Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Sanchez, John Michael ; Contreras, Deisy ; Morgan, Margie Ann</creator><creatorcontrib>Sanchez, John Michael ; Contreras, Deisy ; Morgan, Margie Ann</creatorcontrib><description>Abstract Background Multidrug-resistant gram-negative bacilli are a significant public health threat, associated with 2.2 million deaths worldwide. Of particular importance is the rise of carbapenem-resistant gram-negative bacilli (CRGNB) given the limited options for treatment. The 30-day mortality associated with carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, and carbapenem-resistant Acinetobacter baumannii ranges from 16 to 24%. In recognition of the substantial danger of these organisms, the World Health Organization has designated three CRGNB as Critical Priority pathogens. Methods Based on culture data and antimicrobial susceptibility testing, patients with CRGNB at Cedars-Sinai Medical Center from December 2022 to April 2023 were identified. Clinical data including patient demographics, prior carbapenem use, isolation of additional antibiotic-resistant organisms, subsequent antibiotic therapy, and mortality were compared among CRGNB. Results Of over 65 isolates, the largest proportion of isolates were cultured from pulmonary sources (44%), followed by urine (34%), skin (12%), blood (6%), and abdominal sources (4%). The most prevalent CRGNB isolated were Pseudomonas aeruginosa (65%), Escherichia coli (13%), and Klebsiella pneumoniae (7%). A majority of patients with CRGNB had prior documented carbapenem use (74%) and 71% of CRGNB were associated with at least one other antibiotic resistant organism. Cefiderocol was used to treat 12% of cases. However, 24% of CRGNB were not treated with antibiotics, often with the rationale that the isolate was likely a colonizing strain. The mortality rate among patients with CRGNB during our observation period was 18%. Conclusion CRGNB are emerging pathogens associated with prior carbapenem use and result in significant mortality. Subsets of organisms from our dataset will be further studied for relatedness using Fourier-Transform infrared spectroscopy and whole genome sequencing. Disclosures All Authors: No reported disclosures</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofad500.1806</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Sanchez, John Michael</creatorcontrib><creatorcontrib>Contreras, Deisy</creatorcontrib><creatorcontrib>Morgan, Margie Ann</creatorcontrib><title>2184. Clinical and Molecular Epidemiology of Carbapenem-Resistant Gram-Negative Bacilli in a Los Angeles Tertiary Medical Center</title><title>Open forum infectious diseases</title><description>Abstract Background Multidrug-resistant gram-negative bacilli are a significant public health threat, associated with 2.2 million deaths worldwide. Of particular importance is the rise of carbapenem-resistant gram-negative bacilli (CRGNB) given the limited options for treatment. The 30-day mortality associated with carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, and carbapenem-resistant Acinetobacter baumannii ranges from 16 to 24%. In recognition of the substantial danger of these organisms, the World Health Organization has designated three CRGNB as Critical Priority pathogens. Methods Based on culture data and antimicrobial susceptibility testing, patients with CRGNB at Cedars-Sinai Medical Center from December 2022 to April 2023 were identified. Clinical data including patient demographics, prior carbapenem use, isolation of additional antibiotic-resistant organisms, subsequent antibiotic therapy, and mortality were compared among CRGNB. Results Of over 65 isolates, the largest proportion of isolates were cultured from pulmonary sources (44%), followed by urine (34%), skin (12%), blood (6%), and abdominal sources (4%). The most prevalent CRGNB isolated were Pseudomonas aeruginosa (65%), Escherichia coli (13%), and Klebsiella pneumoniae (7%). A majority of patients with CRGNB had prior documented carbapenem use (74%) and 71% of CRGNB were associated with at least one other antibiotic resistant organism. Cefiderocol was used to treat 12% of cases. However, 24% of CRGNB were not treated with antibiotics, often with the rationale that the isolate was likely a colonizing strain. The mortality rate among patients with CRGNB during our observation period was 18%. Conclusion CRGNB are emerging pathogens associated with prior carbapenem use and result in significant mortality. Subsets of organisms from our dataset will be further studied for relatedness using Fourier-Transform infrared spectroscopy and whole genome sequencing. Disclosures All Authors: No reported disclosures</description><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqNkMFOwzAMhiMEEtPYA3DLA9CRpEvXHkc1BtIGEhrnykmcKShtpqQg7caj07EdOHKxLcu_f_sj5JazKWdVfh-sM0MAI9nQKVlxQUYiF2VWVnJ--ae-JpOUPhhjnDPJ5tWIfAtezqa09q5zGjyFztBN8Kg_PUS63DuDrQs-7A40WFpDVLDHDtvsDZNLPXQ9XUVosxfcQe--kD6Adt476joKdB0SXXQ79JjoFmPvIB7oBs2vVY1dj_GGXFnwCSfnPCbvj8tt_ZStX1fP9WKdaS5EkSldVUZKNUMJqpDClppLI3LDlcDSSgNMzAUvlBm-E9IonZdQcqbBCqtEno8JP-3VMaQU0Tb76Nrhnoaz5kixOVJszhSbI8VBc3fShM_9P8Z_AGRRdok</recordid><startdate>20231127</startdate><enddate>20231127</enddate><creator>Sanchez, John Michael</creator><creator>Contreras, Deisy</creator><creator>Morgan, Margie Ann</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20231127</creationdate><title>2184. Clinical and Molecular Epidemiology of Carbapenem-Resistant Gram-Negative Bacilli in a Los Angeles Tertiary Medical Center</title><author>Sanchez, John Michael ; Contreras, Deisy ; Morgan, Margie Ann</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1226-bc99d55b4e5ab652f8c15d23d1b2e8f5da027216bd00025dbc38a810caf2fb233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanchez, John Michael</creatorcontrib><creatorcontrib>Contreras, Deisy</creatorcontrib><creatorcontrib>Morgan, Margie Ann</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>CrossRef</collection><jtitle>Open forum infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanchez, John Michael</au><au>Contreras, Deisy</au><au>Morgan, Margie Ann</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>2184. Clinical and Molecular Epidemiology of Carbapenem-Resistant Gram-Negative Bacilli in a Los Angeles Tertiary Medical Center</atitle><jtitle>Open forum infectious diseases</jtitle><date>2023-11-27</date><risdate>2023</risdate><volume>10</volume><issue>Supplement_2</issue><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>Abstract Background Multidrug-resistant gram-negative bacilli are a significant public health threat, associated with 2.2 million deaths worldwide. Of particular importance is the rise of carbapenem-resistant gram-negative bacilli (CRGNB) given the limited options for treatment. The 30-day mortality associated with carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, and carbapenem-resistant Acinetobacter baumannii ranges from 16 to 24%. In recognition of the substantial danger of these organisms, the World Health Organization has designated three CRGNB as Critical Priority pathogens. Methods Based on culture data and antimicrobial susceptibility testing, patients with CRGNB at Cedars-Sinai Medical Center from December 2022 to April 2023 were identified. Clinical data including patient demographics, prior carbapenem use, isolation of additional antibiotic-resistant organisms, subsequent antibiotic therapy, and mortality were compared among CRGNB. Results Of over 65 isolates, the largest proportion of isolates were cultured from pulmonary sources (44%), followed by urine (34%), skin (12%), blood (6%), and abdominal sources (4%). The most prevalent CRGNB isolated were Pseudomonas aeruginosa (65%), Escherichia coli (13%), and Klebsiella pneumoniae (7%). A majority of patients with CRGNB had prior documented carbapenem use (74%) and 71% of CRGNB were associated with at least one other antibiotic resistant organism. Cefiderocol was used to treat 12% of cases. However, 24% of CRGNB were not treated with antibiotics, often with the rationale that the isolate was likely a colonizing strain. The mortality rate among patients with CRGNB during our observation period was 18%. Conclusion CRGNB are emerging pathogens associated with prior carbapenem use and result in significant mortality. Subsets of organisms from our dataset will be further studied for relatedness using Fourier-Transform infrared spectroscopy and whole genome sequencing. Disclosures All Authors: No reported disclosures</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/ofid/ofad500.1806</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2328-8957
ispartof Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)
issn 2328-8957
2328-8957
language eng
recordid cdi_crossref_primary_10_1093_ofid_ofad500_1806
source DOAJ Directory of Open Access Journals; Oxford Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; PubMed Central
title 2184. Clinical and Molecular Epidemiology of Carbapenem-Resistant Gram-Negative Bacilli in a Los Angeles Tertiary Medical Center
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T15%3A40%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=2184.%20Clinical%20and%20Molecular%20Epidemiology%20of%20Carbapenem-Resistant%20Gram-Negative%20Bacilli%20in%20a%20Los%20Angeles%20Tertiary%20Medical%20Center&rft.jtitle=Open%20forum%20infectious%20diseases&rft.au=Sanchez,%20John%20Michael&rft.date=2023-11-27&rft.volume=10&rft.issue=Supplement_2&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofad500.1806&rft_dat=%3Coup_cross%3E10.1093/ofid/ofad500.1806%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/ofid/ofad500.1806&rfr_iscdi=true